Rivastigmine tartrate (Exelon drug, Novar-tis) has been approved for patients with mild-to-moderate dementia associated with Parkinson’s disease (PD). Rivastig-mine was previously approved for the treatment of mild-to-moderate dementia of the Alzheimer’s type. Steven Galson, MD, MPH, Director of the FDA’s Center for Drug Evaluation and Research, explains that dementia associated with PD differs from dementia [...]
The FDA has approved an IV formulation of levetiracetam (Keppra tablet, UCB) solution as an infusion for the adjunctive use in the treatment of partial-onset seizures in adults with epilepsy. The 100-mg/ml injection is intended as an alternative when oral administration of levetiracetam is temporarily not feasible. When patients are switched from the oral to [...]
Tinidazole (Tindamax generic, Mission Phar-macal) has been approved for the treatment of bacterial vaginosis (BV), the most common vaginal infection among women of childbearing age in the U.S. This is the first new oral therapy to be approved for the treatment of BV in a decade. It provides a shorter course of oral therapy, with [...]
Novartis has received the FDA’s approval for its generic rivastigmine tartrate (Exelon drug) skin patch for patients with mild-to-moderate Alzheimer’s disease. The company said that the patch was designed with compliance in mind and was preferred to capsules by more than 70% of doctors and nurses as a method of drug delivery. The patch is [...]
